Jeffrey Lockman
About Jeffrey Lockman
Jeffrey Lockman is the Global Regulatory Lead at Bristol-Myers Squibb Company in Princeton, NJ, with extensive experience in regulatory strategy and leadership across multiple pharmaceutical companies.
Title and Current Role
Jeffrey Lockman currently holds the position of Global Regulatory Lead at Bristol-Myers Squibb Company, based in Princeton, NJ. In this capacity, he provides expert regulatory leadership across development teams, facilitating informed decision-making and mitigating risks within the pharmaceutical development process.
Professional Experience at Bristol-Myers Squibb Company
Jeffrey Lockman's tenure at Bristol-Myers Squibb Company includes various strategic roles. He served as Associate Director, United States Strategy Lead -- Cardiovascular in 2016 for seven months, and as Global Regulatory Strategy Manager from 2014 to 2016. During these periods, he led asset teams for successful FDA and EMA interactions, harnessing his regulatory expertise to advance cardiovascular therapies and guide global regulatory strategies.
Previous Roles in Pharmaceutical Industry
Before joining Bristol-Myers Squibb, Jeffrey Lockman contributed significantly to several organizations. At Purdue Pharma, he was a Principal Investigator from 2011 to 2014 in Cranbury, NJ. His earlier role at Myriad Pharmaceuticals, Inc. saw him serving as Scientist II from 2005 to 2011. These positions involved leading exploratory research projects and developing new scientific methodologies.
Academic Background and Early Career
Jeffrey Lockman earned his Ph.D. in Chemistry from Yale University, where he also worked as a Graduate Research Assistant from 1998 to 2003. Prior to this, he completed his undergraduate studies in Chemistry at Swarthmore College, obtaining a B.A. from 1994 to 1998. His academic journey commenced at Seaholm High School.
Regulatory Leadership and Achievements
Throughout his career, Jeffrey Lockman has excelled in regulatory leadership. He has led cross-functional, multi-company efforts to submit INDs, respond to FDA queries, and manage multinational Phase 2 studies. His expertise extended to synthesizing post-meeting feedback to inform development planning and developing detailed regulatory risk assessments, ensuring seamless progression of clinical trials and convergence between FDA and EMA commitments.